Database of all ivermectin COVID-19 studies. 60 studies, 23 peer reviewed, 40 with results comparing treatment and control groups. Submit updates/corrections below. FLCCC provides treatment recommendations.

2/15	PrEP <i>Behera</i> et al., R cases, \$\\$3.0\%, p Prophylactic role of ivermectin in SARS Prospective prophylaxis study with 3,532 healthcare workers, 2,199 receiving two-dose iverm
2/15	Early, Covid Analysis meta-analysis v31 Ivermectin is effective for COVID-19: real  • 100% of the 40 studies to date report positive effects. Random effects meta-analysis for ear
2/12	Early <b>Schwartz</b> , E., S <b>hosp.</b> , \$\\$80.7\%, p Ivermectin vs. placebo treatment in non Double blind RCT for mild-moderate COVID-19 outpatients in Israel showing significantly faste
2/10	Late <i>Lima-Morales</i> ( death, \$\psi 77.7\%, p Effectiveness of a multidrug therapy co Prospective trial of 768 COVID-19 outpatients in Mexico, 481 treated with ivermectin, AZ, mon
2/5	Late <i>Bukhari</i> et al., viral+, \\$2.4%, p Efficacy of Ivermectin in COVID-19 Patie  RCT of relatively low risk hospitalized patients with 50 ivermectin and 50 control patients sho
2/2	Early <i>Mohan</i> et al. (P no recov., \162.5 Ivermectin in mild and moderate COVID RCT in India with low risk patients, comparing 24mg ivermectin, 12mg ivermectin, and placeb
1/27	Meta <i>Castaneda-Sab</i> meta-analysis Outcomes of Ivermectin in the treatmen Student-written meta analysis of a very small subset of studies. This is the most biased and fl
1/21	Early <i>Chamie-Quintero</i> et al., <i>Preprint</i> , <i>doi:10</i> Sharp Reductions in COVID-19 Case Fat Analysis of ivermectin usage within states in Peru showing sharp reductions in COVID-19 deat
1/20	In Vit <i>Mody</i> et al., Co <i>in vitro</i> Identification of 3-chymotrypsin like prot Computational molecular modeling screening and <i>in vitro</i> analysis for inhibitory effects on SA
1/19	Late Rezai et al., IR recov. time, \pm21 Effectiveness of Ivermectin in the Treat  RCT in Iran showing shorter time to clinical recovery with Ivermectin. Results are from: [1]
1/19	Meta Hill et al., Rese meta-analysis Meta-analysis of randomized trials of iv  Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose
1/16	Early Raad et al., Chi hosp., \ 85.7%, p In vivo use of ivermectin (IVR) for treat  RCT in Lebanon showing significantly lower viral load at day 3, and lower hospitalization. Resu

1/16	Early <b>Asghar</b> et al., N <b>viral+</b> , <b>\\$2.1%</b> , <b>p</b> Efficacy of Ivermectin in COVID-19 RCT with 103 patients in Pakistan comparing ivermectin and CQ, showing significantly lower
1/13	Early, Kory et al., Fron review Review of the Emerging Evidence Demo  Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has bee
1/12	Late <i>Okumuş</i> et al., <b>death</b> , ↓33.3%, p Ivermectin for Severe COVID-19 Manage Small RCT for severe COVID-19 comparing ivermectin with low dose HCQ+AZ+favipiravir, with
1/11	PrEP <i>Chala</i> et al., NC cases, \$\geq 94.7\%, p Prophylaxis Covid-19 in Healthcare Age Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina with 234 healthcare workers
1/11	N/A <b>Bousquet-Mel dosing study</b> Large Impact of obesity on the dispositi  Animal dosing study with an obese dog model concluding that ivermectin maintenance dose
1/9	Early <i>Kirti</i> et al., med death, ↓88.7%, p Ivermectin as a potential treatment for RCT with 112 mild and moderate COVID-19 patients in India, showing lower mortality, ventilati
1/8	Early <i>Chamie, J. (Ne</i> news COVID-19 in Mexico Comparison of COVID-19 death rates in Mexico showing that the only state using ivermectin h
1/6	Early <i>Babalola</i> et al., viral+, ↓63.9%, p Ivermectin shows clinical benefits in mil Small RCT comparing ivermectin 6mg & 12mg q84hr with lopinavir/ritonavir, showing a statist
1/6	PrEP <i>Hirsch</i> et al., <i>Microbiology &amp; Infectious</i> Ivermectin as Prophylaxis Against COVI Report on ivermectin prophylaxis for healthcare workers in a hospital in Argentina, showing 0
1/3	Early, Lawrie et al., Pr meta-analysis Ivermectin reduces the risk of death fro  Meta analysis confirming the effectiveness of ivermectin for COVID-19, showing ivermectin tre
12/31	Animal <i>Madrid</i> et al., H animal study Safety of oral administration of high dos In vivo analysis of the safety of high dose ivermectin with a Corydoras fish animal model.
12/30	Revie <i>McCullough</i> et review Multifaceted highly targeted sequential Review urging early treatment of COVID-19 with sequential multidrug treatment that has been
12/30	Early <b>Procter</b> et al., Reviews in Cardiovascul Clinical outcomes after early ambulatory Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbidities, showin
12/27	Meta <i>Hill, A., Preprint</i> meta-analysis Meta-analysis of clinical trials of iverme WHO-funded meta analysis showing ivermectin treatment mortality relative risk RR 0.17 [0.08
12/24	In Vit Jeffreys et al., in vitro Remdesivir-Ivermectin combination dis

In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination.

12/20	PrEP <i>Vallejos et al.,</i> <b>cases,</b> \$\pm\$ <b>73.6%, p</b> Ivermectin to prevent hospitalizations in Report on ivermectin + carrageenan prophylaxis in a hospital in Argentina showing lower case
12/18	Early, <i>Kory</i> et al., <i>FLC</i> <b>meta-analysis</b> Review of the Emerging Evidence Demo Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has bee
12/15	PrEP Alam et al., Eur cases, \$\gup\$90.6%, p Ivermectin as Pre-exposure Prophylaxis 91% reduction in COVID-19 cases with ivermectin prophylaxis. 118 healthcare workers in Ban
12/15	Early Afsar et al., SS symptoms, \$\gup\$92 Ivermectin Use Associated with Reduce  Small 95 patient study in Pakistan adding ivermectin to standard of care (HCQ+AZ) for outpati
12/11	Early <i>Hussain</i> et al., International Journal of Outcome of ivermectin and doxycycline Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becomin
12/7	Early <i>Chaccour</i> et al symptoms, ↓52 The effect of early treatment with iverm  Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single
12/4	In Vit Surnar et al., A in vitro Clinically Approved Antiviral Drug in an O  In Vitro analysis of ivermectin with orally administrable nanoparticles showing efficacy for dec
12/2	Early Ahmed et al., In symptoms, \185 A five day course of ivermectin for the tr
	Small 72 patient RCT of ivermectin and ivermectin + doxycycline showing faster recovery with
12/2	Small 72 patient RCT of ivermectin and ivermectin + doxycycline showing faster recovery with  Early <i>Chamie, J. (Ne</i> news The effect of using ivermectin to control  After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has see
12/2	Early <i>Chamie, J. (Ne</i> news The effect of using ivermectin to control
	Early <i>Chamie</i> , <i>J. (Ne</i> news The effect of using ivermectin to control  After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has see  Early <i>Alonso</i> et al., ( death, \$\geq 91.8\%, p COVID-19: Uso de ivermectina
12/1	Early <i>Chamie, J. (Ne</i> news The effect of using ivermectin to control  After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has see  Early <i>Alonso et al., (</i> death, \$\geq 91.8\%, p COVID-19: Uso de ivermectina  Observational study in Argentina showing significantly lower mortality in the 60 days after ado  PrEP <i>Bernigaud et al</i> death, \$\geq 99.4\%, p Ivermectin benefit: from scabies to COV
12/1 11/28	Early <i>Chamie, J. (Ne</i> news The effect of using ivermectin to control  After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has see  Early <i>Alonso</i> et al., ( death, ↓91.8%, p COVID-19: Uso de ivermectina  Observational study in Argentina showing significantly lower mortality in the 60 days after ado  PrEP <i>Bernigaud</i> et al death, ↓99.4%, p Ivermectin benefit: from scabies to COV  69 residents of a French care home, median age 90, were treated with ivermectin for a scabie  PrEP <i>Hellwig</i> et al., l cases, ↓78.0%, p A COVID-19 Prophylaxis? Lower inciden
12/1 11/28 11/28	Early <i>Chamie, J. (Ne</i> news The effect of using ivermectin to control  After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has see  Early <i>Alonso</i> et al., ( death, ↓91.8%, p COVID-19: Uso de ivermectina Observational study in Argentina showing significantly lower mortality in the 60 days after ado  PrEP <i>Bernigaud</i> et al death, ↓99.4%, p Ivermectin benefit: from scabies to COV 69 residents of a French care home, median age 90, were treated with ivermectin for a scabie  PrEP <i>Hellwig</i> et al., l cases, ↓78.0%, p A COVID-19 Prophylaxis? Lower inciden Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infecti  Late <i>Niaee</i> et al., Re death, ↓81.8%, p Ivermectin as an adjunct treatment for h

11/18	Late <i>Budhiraja</i> et al., death, ↓99.1%, p Clinical Profile of First 1000 COVID-19 C Retrospective 976 hospitalized patients with 34 treated with ivermectin showing ivermectin m
11/17	PrEP <i>Carvallo et al.</i> , <b>cases</b> , <b>199.9%</b> , <b>p</b> Study of the Efficacy and Safety of Topi Prophylaxis study using ivermectin and carrageenan showing 0 of 788 cases from treated he
11/14	Late <i>Spoorthi</i> et al., recov. time, \21 Utility of Ivermectin and Doxycycline co  100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom r
11/13	PrEP <i>Elgazzar</i> et al., cases, \$\pm\$80.0%, p Efficacy and Safety of Ivermectin for Tre RCT for prophylaxis with ivermectin showing a significant reduction in cases with treatment. R
11/13	Late <i>Elgazzar</i> et al., death, \$\psi\$91.7%, p Efficacy and Safety of Ivermectin for Tre RCT comparing ivermectin + SOC vs. HCQ + SOC, showing a significant reduction in mortality
11/11	Late <i>Camprubí</i> et al ICU, \$\graph\$33.3%, p=1 Lack of efficacy of standard doses of iv  Tiny 26 patients retrospective study of ivermectin 200 μg/kg, median 12 days after symptom
11/11	Early Krolewiecki et al., SSRN (Preprint) Antiviral Effect of High-Dose Ivermectin i  Viral load RCT finding a concentration dependent antiviral activity of oral high dose ivermectin
11/10	Revie <i>Turkia, M., Res</i> <b>review</b> FLCCC Alliance MATH+ ascorbic acid a Review suggesting ivermectin should be used based on existing data suggesting significant b
11/4	Early <i>Cadegiani</i> et al death, ↓78.3%, p Early COVID-19 Therapy with Azithromy Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall cli
11/3	Early, <i>Morgenstern</i> et al., J. Clinical Trials (pr The Use of Compassionate Ivermectin i Retrospective 3,099 outpatients treated with ivermectin in an ER. Of 2,706 treated on an outp
11/3	PrEP <i>Behera</i> et al., cases, \$\pm\$49.7%, p Role of ivermectin in the prevention of C Retrospective prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare worke
11/2	Animal Arévalo et al., b animal study Ivermectin reduces coronavirus infectio  Mouse study showing ivermectin reducing MHV viral load and disease. MHV is a type 2 family
10/31	PrEP <i>Chang</i> et al., ResearchGate ( <i>Preprint</i> ) COVID-19: Effectiveness of pre-exposur Pre-exposure prophylaxis study with 129 people split into high/low exposure groups, with eac
10/26	Late <i>Hashim</i> et al., death, \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
10/22	PrEP Guerrero et al., Colombia Médica, doi:1 COVID-19: The Ivermectin African Enigma

Study of African Programme for Onchocerciasis Control (APOC) countries, which used iverme...

10/19	PrEP Carvallo et al., cases, ↓96.3%, p Usefulness of Topic Ivermectin and Carr Prophylaxis study using ivermectin and carrageenan showing 0 of 131 cases from treated he
10/13	Late <i>Rajter</i> et al., Ch death, ↓46.0%, p Use of Ivermectin is Associated with Lo Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24
10/9	Late <i>Mahmud</i> et al., death, \$\psi 85.8\%, p Clinical Trial of Ivermectin Plus Doxycycl RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, an
10/8	Theo Francés-Moner theory Has Ivermectin Virus-Directed Effects a In silico study showing that ivermectin is capable of interfering in different key steps of the SA
10/8	Late Soto-Becerra e death, \$\psi\$17.1%, p Real-World Effectiveness of hydroxychlo Retrospective database study of 5683 patients, 692 received HCQ/CQ+AZ, 200 received HCQ
9/30	Late <i>Chachar</i> et al., I no recov., \$\gu\$10.0 Effectiveness of Ivermectin in SARS-Co Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in re
9/24	Late <i>Khan</i> et al., Arc death, ↓87.0%, p Ivermectin treatment may improve the p Retrospective 115 ivermectin patients and 133 control patients showing significantly lower de
9/22	In Vit Li et al., J. Cell in vitro Quantitative proteomics reveals a broad  In Vitro study showing Ivermectin is a safe wide-spectrum antiviral against SARS-CoV-2, huma
9/15	Early <i>Carvallo</i> et al., death, \$1.9%, p Safety and Efficacy of the combined us Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin. There was one death
9/15	Revie Jans et al., Cell review Ivermectin as a Broad-Spectrum Host-Di  Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, i
9/3	Late <b>Podder</b> et al., I recov. time, \$\pm\$16 Outcome of ivermectin treated mild to Small RCT with 32 ivermectin patients and 30 control patients. The mean recovery time after
8/28	PrEP Shouman et al., symp. case, \$\gu\$91 Use of Ivermectin as a Potential Chemo  PEP trial for asymptomatic close contacts of COVID-19 patients, 203 ivermectin patients and
8/15	Early <i>Espitia-Hernan</i> viral+, \$\psi\$97.2%, p Effects of Ivermectin-azithromycin-chole Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patie
8/14	Late <i>Bhattacharya</i> et al., Int. J. Scientific Re Observational Study on Clinical Features Retrospective 148 hospitalized patients showing triple therapy with ivermectin + atorvastatin

7/31	Late <i>Chang</i> et al., ResearchGate (Preprint) Post-acute or prolonged COVID-19: iver  Report on 33 patients with persistent or post-acute symptoms treated with ivermectin, showi
7/31	Theo <i>Chang</i> et al., R theory COVID-19: Post-exposure prophylaxis wi Proposed PEP protocol based on ivermectin.
7/31	Late Alam et al., Journal of Bangladesh Coll A Case Series of 100 COVID-19 Positive  Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, d
7/31	Late <b>Rahman</b> et al., J. Bangladesh Coll. Phy Comparison of Viral Clearance between Comparison of 200 patients treated with ivermectin + doxycycline and 200 treated with HCQ
7/14	Early <i>Chowdhury</i> et al., Research Square, do A Randomized Trial of Ivermectin-Doxyc Small 116 patient RCT comparing Ivermectin-Doxycycline and HCQ+AZ, not showing a signific
7/8	Late <i>Gorial</i> et al., m death, ↓71.0%, p Effectiveness of Ivermectin as add-on T Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin showin
6/30	In Vit <i>Caly</i> et al., Anti <i>in vitro</i> The FDA-approved drug ivermectin inhib <i>In Vitro</i> study showing that ivermectin is an inhibitor of SARS-CoV-2, with a single addition to V
6/19	Theo Lehrer et al., In theory Ivermectin Docks to the SARS-CoV-2 Sp In silico analysis showing ivermectin docking which may interfere with the attachment of the s
6/12	Revie <i>Heidary</i> et al., <b>review</b> Ivermectin: a systematic review from an Review of the antimicrobial, antiviral, and anti-cancer properties of ivermectin. Antiviral effects
5/2	Early <i>Chang, G., Research Gate, doi:10.1314</i> Inclusión de la ivermectina en la primera Peru observational case study of 7 patients treated with ivermectin, showing improvement an

For search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), PRISMA answers, and statistical methods see ivmmeta.com. In Vitro, Ex Vivo, Meta, Theory, Safety, Review, and News items are not included in the study count. There is a total of 80 items. Studies with preprints and journal versions are listed under the earlier preprint date.

6 sur 6